Stock Watch: Oncology Sands Shift At AstraZeneca And Merck
When Oncology Dominates Sales, Comparisons Become Obvious
Executive Summary
When AstraZeneca closed out big pharma earnings season, its usually dominant therapeutic franchise missed analysts’ expectations. Merck’s, on the other hand, did not disappoint.